Find in Library

The objective was to study the occurrence of perioperative cardiovascular complications (CVС) and clinical and laboratory cardioprotection parameters in patients treated with an infusion of a succinate-containing drug during the intraoperative period of vascular surgery.Materials and methods. The study involved 120 patients with high cardiac risk (revised cardiac risk index  > 2, risk of perioperative myocardial infarction or cardiac arrest  > 1 %) who underwent elective vascular surgery. Patients were randomly divided into two groups. Patients of group 1 received intraoperative infusion of succinate-containing drug at a dose of succinate 0.35 [0.26–0.40] mg/kg/min– 1. Group II was a control group. In the perioperative period, the occurrence of perioperative CVC, the blood level of the N-terminal segment of natriuretic B-type prohormone (NT-proBNP) and cardiospecific troponin I (cTnI) were analyzed.Results.  Perioperative CVC was registered in 11 (18.3 %) patients of group I and in 11 (18.3 %) patients of group II (p   =  1.0). The level of NT-proBNP in patients of group I and group II was 207  [160–300] pg/ml and 229  [150.6–298.9] pg/ml (p   =   0.817) before surgery, 234.2 [155.9–356] and 277 [177.7–404] pg/ml ( p   =  0.207) after surgery and 240.5[149.3–306] and 235.5 [133–495.1] pg/ml ( p   =  0.979) before discharge from the hospital. An increased level of cTnI after surgery was recorded in 4 (6.7 %) patients of group I and in 1 (1.7 %) patient ( p   =  0.364) of group II.Conclusion. Intraoperative infusion of succinate-containing drug does not affect the occurrence of CVC in patients with high cardiac risk during vascular surgery. The succinate-containing drug does not affect the preoperative level of NT-proBNP and cTnI.